CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project innovates drug delivery systems targeting sphingomyelinase in atherosclerotic plaques, aiming to reduce systemic side effects. It develops a unique liposome formulation that releases drugs in response to the enzyme, potentially transforming treatment for various diseases linked to sphingomyelin dysregulati…
Cardiovascular diseases are the world’s number one killer, causing 43% of all deaths and costing the EU 192 billion Euros annually.
Delaying their progression using e.g. targeted drug delivery to atherosclerotic plaques is a number one priority in modern healthcare.The enzyme sphingomyelinase (SMase) is upregulated in atherosclerotic plaques.
In vivo, dysregulation of enzymatic conversion of the cell membrane phospholipid sphingomyelin (SM) to ceramide by SMase leads to a change in ceramide con…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
